Studies Advancemed Research Has Conducted That Have Received FDA Approval

Studies AdvanceMed Research has conducted that have received FDA approval

Bio-T-Gel (testosterone gel); Teva Pharmaceuticals; For the treatment of hypogonadism, Approved February 2012

Myrbetriq (mirabegron); Astellas Pharma US, Inc.; For the treatment of overactive bladder, Approved June 2012

Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012

Xtandi (enzalutamide); Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012

Anturol (oxybutynin) Gel; Antares Pharma; For the treatment of overactive bladder, Approved December 2011

Zytiga (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011

Fortesta (testosterone gel); Endo Pharmaceuticals; For the treatment of hypogonadism, Approved December 2010

Jalyn (dutasteride + tamsulosin); GlaxoSmithKline; For the treatment of benign prostatic hyperplasia, Approved June 2010

Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010

Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010

Xgeva (denosumab); Amgen; For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010

Gelnique (oxybutynin chloride); Watson Pharmaceuticals; For the treatment of overactive bladder, Approved January 2009

D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 1 of 3 Studies AdvanceMed Research has conducted that have received FDA approval

Toviaz (fesoterodine fumarate); Pfizer; For the treatment of overactive bladder, Approved October 2008

Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008

No approvals recorded for Urology in 2005.

Sanctura (trospium chloride); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Indevus Pharmaceuticals; Approved May, 2004

Vesicare (solifenacin succinate); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Yamanouchi, GlaxoSmithKline; Approved November, 2004

Oxytrol (oxybutynin transdermal system); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.; Watson Pharmaceuticals; Approved March 2003

UroXatral (alfuzosin HCl extended-release tablets); For the treatment of of the signs and symptoms of benign prostatic hyperplasia; Sanofi-Synthelabo; Approved June 2003

Crestor (rosuvastatin calcium); AstraZeneca; For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia, Approved August 2003

Levitra (vardenafil); Bayer, GlaxoSmithKline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003

Eligard (leuprolide acetate); For the palliative treatment of advanced prostate cancer; Atrix Laboratories; Approved January 2002

D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 2 of 3 Studies AdvanceMed Research has conducted that have received FDA approval

Dutasteride; For the treatment of symptomatic benign prostatic hyperplasia; GlaxoSmithKline; Approved November 2001

Detrol LA (tolterodine tartrate); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency; Pharmacia & Upjohn; Approved December 2000

Ditropan XL (oxybutynin chloride); Treatment for overactive bladder; Alza; Approved June 1999

Detrol tablets; Treatment for an overactive bladder; Pharmacia & Upjohn; Approved March 1998

Ditropan XL Tablets; Treatment for and Overactive Bladder; Alza; Approved December 1998

Proscar; Treatment for complication relating to benign prostatic hyperplasia (BPH); Merck; Approved April 1998

D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 3 of 3